Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T21:11:41.599Z.
Calculation as of: 2026-10-06T21:11:41.599Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: df0d51bc4c7c4fe031789de0e9442acf829cec50a05ec95901a80cda74a8a9f3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$3.06B
EBITDA Yield
N/A
TTM Avg
0.89%
3Y Avg
0.89%
5Y Avg
0.89%
Market Cap
$2.99B
EBITDA Yield
1.21%
TTM Avg
0.54%
3Y Avg
0.54%
5Y Avg
0.54%
Market Cap
$3.12B
EBITDA Yield
N/A
TTM Avg
127.06%
3Y Avg
127.06%
5Y Avg
127.06%
Market Cap
$2.77B
EBITDA Yield
3.72%
TTM Avg
2.99%
3Y Avg
2.18%
5Y Avg
2.18%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.03B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | N/A | 0.89% | 0.89% | 0.89% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 1.21% | 0.54% | 0.54% | 0.54% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | N/A | 127.06% | 127.06% | 127.06% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | N/A | N/A | N/A | N/A |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.77B | 3.72% | 2.99% | 2.18% | 2.18% |
| CareDx, Inc (CDNA)vs › | $3.30B | 0.53% | 4.11% | 5.67% | 5.67% |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | N/A | N/A | N/A | N/A |
| AtriCure, Inc. (ATRC)vs › | $2.73B | 1.32% | 1.25% | 1.25% | 1.25% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
